CervoMed to Participate in Upcoming Investor Conferences

CervoMed Inc. (NASDAQ: CRVO), a biotechnology firm specializing in treatments for age-related brain disorders, is set to engage with investors during two conferences in March 2026. Firstly, the company will participate in the Leerink Global Healthcare Conference on March 11, 2026, where management will hold 1x1 investor meetings. Subsequently, CervoMed will take part in the 38th Annual ROTH Conference on March 23, 2026, with a scheduled fireside chat from 12:00 to 12:30 PM PT, followed by additional 1x1 investor meetings. The fireside chat will be available via webcast on the company’s investor relations website.

CervoMed focuses on the development of its lead drug candidate, neflamapimod, which is an oral small molecule designed to address critical pathways implicated in neuroinflammation and neurodegeneration, fundamental processes in degenerative brain disorders. The company recently completed its Phase 2b RewinD-LB trial evaluating neflamapimod in patients with Dementia with Lewy Bodies (DLB) who exhibit a low likelihood of Alzheimer's disease co-pathology. Building on these results, CervoMed aims to launch a global pivotal Phase 3 trial for the same patient demographic in the latter half of 2026, pending the availability of funding.

As CervoMed prepares for these investor conferences, the focus remains on showcasing the potential of neflamapimod and the company’s commitment to advancing treatments for age-related brain disorders. For inquiries, media representatives can contact Lisa Guiterman at Biongage Communications, while investor relations can be directed to Argot Partners.

CervoMed Inc. (NASDAQ: CRVO) is poised to capture investor attention as it participates in key healthcare conferences this March, notably the Leerink Global Healthcare Conference and the 38th Annual ROTH Conference. For investors considering a position in CervoMed, this is a critical moment to assess both the company’s strategic direction and its therapeutic innovations targeting age-related brain disorders.

CervoMed's lead candidate, neflamapimod, is gaining traction as a potential treatment for degenerative brain disorders by addressing neuroinflammation, a core process in diseases like dementia with Lewy bodies (DLB). The company's recent completion of the Phase 2b RewinD-LB trial underscores its commitment to advancing this promising therapeutic avenue. The upcoming pivotal Phase 3 trial scheduled for late 2026 is a key catalyst that could greatly influence the stock price, contingent upon securing adequate funding.

Investors should particularly pay attention to management’s insights during these investor conferences. The format—1x1 meetings at the Leerink conference and a fireside chat at the ROTH conference—will provide opportunities for in-depth discussions, strategic vision, and possibly, updates on funding progress for the Phase 3 trial.

Given the significant unmet need for effective treatments in age-related neurodegenerative diseases, CervoMed’s innovation pipeline is well-positioned in a growing market. However, investors should remain cognizant of the inherent risks associated with clinical trials and the biotechnology sector, including funding fluctuations and regulatory hurdles.

As CervoMed's management engages with the investment community, potential investors should monitor the outcomes of these conferences closely. They may offer critical insights that could define the company’s trajectory in the ongoing quest to address pressing healthcare needs in aging populations. Therefore, evaluating both the advancements in CervoMed’s clinical programs and the discussions during these conferences is essential for making informed investment decisions.